Developer / Researcher,Treatment vs. Vaccine,Product Category,Stage of Development,Anticipated Next Steps,Product Description,Clinical Trials for COVID-19,Funder,Published Results,Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only),FDA-Approved Indications,Sources,Date Last Updated
Zydus Cadila Healthcare Limited ,Vaccine,DNA-based,Phase III,"Phase III dosed January 2021; Pre-clinical results released January 2021; DCGI approved start of Phase III trial in January 2021; Phase I/II study: Phase I began July 2020 and Phase II began August 2020, initial results expected September 2020",DNA; (ZyCoV-D) plasmid vaccine ,"CTRI/2020/07/026352, CTRI/2021/01/030416",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/31/2021
Inovio Pharmaceuticals/ Beijing Advaccine Biotechnology/ VGXI Inc./ Richter-Helm BioLogics/ Ology Bioservices/ International Vaccine Institute/ Seoul National University Hospital/ Thermo Fisher Scientific/ Kaneka Eurogentec,Vaccine,DNA-based,Phase II/III,"Phase I data published December 2020; Phase II dosed December 2020, as part of its Phase II/III clinical trial (INNOVATE); FDA partial clinical hold for planned Phase II/III trial reported on 9/28/2020; Phase I/IIa trial began July 2020; Animal study results released July 2020; Joined US Operation Warp Speed in June 2020; Phase I began April 2020, interim data of ongoing study released June 2020",DNA; (INO-4800) plasmid vaccine with electroporation ,"ChiCTR2000038152, ChiCTR2000040146, NCT04336410, NCT04447781, NCT04642638",Coalition for Epidemic Preparedness (CEPI) / Gates Foundation / US Department of Defense,"Inovio (http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Announces-Positive-Interim-Phase-1-Data-For-INO-4800-Vaccine-for-COVID-19/default.aspx), EClinicalMedicine (https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30433-8/fulltext)",Same platform as multiple vaccine candidates,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/31/2021
Osaka University/ AnGes/ Takara Bio/ Cytiva/ Brickell Biotech,Vaccine,DNA-based,Phase II/III,"Phase II/III trial began December 2020; Pre-clinical study results released October 2020; Phase I/II trials began end of June (AG0301) and August (AG0302) 2020, results expected during Q1 2021",DNA; (AG0301 & AG0302) plasmid vaccine + adjuvant ,"jRCT2051200085,  jRCT2051200088, NCT04463472, NCT04527081, NCT04655625",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/31/2021
"GeneOne
  Life Science",Vaccine,DNA-based,Phase I/II,Phase I/IIa began December 2020,DNA; (GLS-5310),NCT04673149,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/18/2021
"Genexine Consortium (GenNBio, International Vaccine Institute, Korea Advanced Institute of Science and Technology (KAIST), Pohang University of Science and Technology (POSTECH)/ Binex/ PT Kalbe Pharma",Vaccine,DNA-based,Phase I/II,Updated development plan to GX-19N formula and will reconduct Phase I/IIa study as of December 2020. Phase I of Phase I/IIa study began end of June 2020; Animal study results announced August 2020,DNA; (formerly GX-19) (GX-19N) ,"NCT04445389, NCT04715997",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/31/2021
OncoSec Medical Incorporated / Providence Cancer Institute ,Vaccine,DNA-based,Phase I,Phase I dosed January 2021,"(CORVax12), IL-12 expression platform + “S” glycoprotein ",NCT04627675,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/2/2021
Symvivo,Vaccine,DNA-based,Phase I,Phase I dosed November 2020,DNA; bacTRL-Spike,NCT04334980,National Research Council of Canada Industrial Research Assistance Program (NRC IRAP),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/2/2020
BioNet Asia/ Technovalia/ Vax4COVID/ The University of Sydney/ The University of Western Australia/ Telethon Kids Institute/ PharmaJet,Vaccine,DNA-based,Pre-clinical,Phase I expected to begin February 2021,DNA; (COVIGEN) needle-free delivery,NCT04742842,Australian Government Medical Research Future Fund (MRFF),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/16/2021
Chula Vaccine Research Center,Vaccine,DNA-based,Pre-clinical,Unknown,DNA with electroporation,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/23/2020
Ege University Drug Development and Pharmacokinetic Research Application Center (ARGEFAR)/ Scientific and Technological Research Council of Turkey (TUBITAK),Vaccine,DNA-based,Pre-clinical,Unknown,DNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/23/2020
Entos Pharmaceuticals/ Cytiva,Vaccine,DNA-based,Pre-clinical,Phase I/II expected to begin March 2021,DNA; (Covigenix),NCT04591184,Canadian Institutes of Health Research (CIHR)/ Research Nova Scotia (RNS)/ Institute for Ageing (IA)/ National Research Council of Canada Industrial Research Assistance Program (NRC IRAP),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/27/2021
"Globe Biotech Limited, Bangladesh",Vaccine,DNA-based,Pre-clinical,Unknown,DNA plasmid vaccine,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/9/2020
Immunomic Therapeutics/ EpiVax/ PharmaJet,Vaccine,DNA-based,Pre-clinical,Unknown,"DNA; plasmid vaccine, needle-free delivery",,Unknown,,Same platform as vaccine candidates for SARS,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Mediphage Bioceuticals/ University of Waterloo/ Lambton College,Vaccine,DNA-based,Pre-clinical,Unknown,DNA; msDNA-VLP,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/23/2020
"National
  Research Centre, Egypt",Vaccine,DNA-based,Pre-clinical,Unknown,"DNA; plasmid vaccine S, S1, S2, RBD & N",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
"National Institute of Chemistry, Slovenia",Vaccine,DNA-based,Pre-clinical,Unknown,"Plasmid DNA, nanostructured RBD",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/9/2020
OPENCORONA Project: Karolinska Institute/ Justus Liebig University Giessen/ Public Health Agency of Sweden (FoHM)/ IGEA/ Cobra Biologics/ Adlego Biomedical/ Region Stockholm,Vaccine,DNA-based,Pre-clinical,Phase I expected to begin in 2020,DNA with electroporation,,European Commission (Horizon 2020 Program),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/23/2020
Scancell/ University of Nottingham/ Nottingham Trent University,Vaccine,DNA-based,Pre-clinical,Phase I COVIDITY clinical trial expected to start as soon as possible during 2021,DNA; plasmid vaccine RBD&N,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/19/2021
"Statens Serum Institute, Denmark",Vaccine,DNA-based,Pre-clinical,Phase I is expected to start in late 2020 or early 2021,DNA; (CoVAXIX) plasmid vaccine,,Folketing's Finance Committee,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/16/2020
Takis/ Applied DNA Sciences/ Evvivax/ Rottapharm Biotech,Vaccine,DNA-based,Pre-clinical,"Phase I/II expected to begin March 2021, announced the authorization of the clinical trial by the Italian Medicines Agency (AIFA) on 2/3/2021; Pre-clinical results released in May and July 2020",DNA (COVID-eVax),EudraCT 2020-003734-20,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/25/2021
University of Cambridge/ DIOSynVax/ PharmaJet,Vaccine,DNA-based,Pre-clinical,Phase I expected to begin late fall 2020 or early 2021,DNA; (DIOS-CoVax2) synthetic gene inserts compatible with multiple delivery systems ,,Innovate UK,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,10/28/2020
Beijing Institute of Biological Products/ Sinopharm ,Vaccine,Inactivated virus,Phase III,"Hungary granted ""emergency use"" approval on 1/29/2021; Pakistan granted ""emergency use authorization"" on 1/18/2021; China ""granted conditional market approval"" on 12/31/2020; Midterm clinical results released on 12/30/2020; Bahrain National Health Regulatory Authority (NHRA) ""approved"" on 12/13/2020; UAE Ministry of Health and Prevention (MOHAP) announced ""official registration"" on 12/9/2020, following review of Phase III interim analysis; Phase I/II results published October 2020; Phase III trial began July 2020; Received early approval for ""emergency use"" in China (Aug 2020) and the UAE (Sep 2020)","Inactivated, (BBIBP-CorV)","ChiCTR2000032459, ChiCTR2000034780, NCT04510207, NCT04560881",Unknown,"The Lancet (https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30831-8/fulltext), National Medical Products Administration (http://english.nmpa.gov.cn/2020-12/30/c_578717.htm)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/31/2021
Bharat Biotech/ Indian Council of Medical Research/ National Institute of Virology/ Ocugen/ Precisa Medicamentos,Vaccine,Inactivated virus,Phase III,"Phase III interim analysis results announced 3/3/2021; Neutralization of UK-variant with vaccine-elicited sera announced January 2021; India granted ""permission for emergency use"" on 01/03/2021; Phase I and II safety and immunogenicity data released December 2020 and published January 2021; Phase III began November 2020; Phase I/II study: Phase I began July 2020 and Phase II began September 2020, initial results expected September 2020; Animal study results released September 2020",Inactivated; whole-virion (COVAXIN) (BBV152),"CTRI/2020/07/026300, NCT04471519, CTRI/2020/09/027674, CTRI/2020/11/028976, NCT04641481",Unknown,"medRxiv (https://www.medrxiv.org/content/10.1101/2020.12.11.20210419v1), medRxiv (https://www.medrxiv.org/content/10.1101/2020.12.21.20248643v1), The Lancet (https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30942-7/fulltext), bioRxiv (https://www.biorxiv.org/content/10.1101/2021.01.26.426986v2)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/4/2021
"Institute of Medical Biology, Chinese Academy of Medical Sciences",Vaccine,Inactivated virus,Phase III,"Phase III dosed (Malaysia) late January 2021; Phase II began June 2020; Phase I began May 2020, results released October 2020",Inactivated,"NCT04412538, NCT04470609, NCT04659239",Unknown,medRxiv (https://www.medrxiv.org/content/10.1101/2020.09.27.20189548v1),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/31/2021
"Research Institute for Biological Safety Problems, Republic of Kazakhstan",Vaccine,Inactivated virus,Phase III,"Kazakhstan granted ""temporary registration for nine months"" as of 1/13/2021; Phase III began December 2020; Phase I/II began September 2020","Inactivated, (QazCovid-in®)","NCT04530357, NCT04691908",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/18/2021
Sinovac/ Instituto Butantan/ Bio Farma,Vaccine,Inactivated virus,Phase III,"China's NMPA granted ""conditional marketing authorization"" on 2/8/2021; Phase III results (Brazil, Turkey, Indonesia, Chile) announced on 2/5/2021; Phase I/II safety, tolerability, and immunogenicity data in adults aged 60 years and older published on 2/3/2021; Sinovac filed for ""conditional market authorization"" with China’s National Medical Products Administration (NMPA) on 2/3/2021; Chile granted ""emergency use"" approval on 1/20/2021; Brazil granted ""temporary authorization for emergency use"" on 1/17/2021; Turkey granted ""emergency use authorization"" on 1/31/2021; Indonesia granted ""emergency use approval"" on 01/11/2021; Phase III efficacy results (Brazil) released early January 2021; Phase I/II complete analysis results published 11/17/2020; Phase III trial resumed in Brazil on 11/11/2020, Phase III trial suspended in Brazil on 11/09/2020; Received approval for Phase I/II trial in adolescents and children in September 2020; Phase III trial began end of July 2020; Phase II began June 2020, mid-phase II results released August 2020; Preliminary results from Phase I/II trials released June and September 2020 (aged 60+) 2020; Received early approval for ""emergency use"" in China (Aug 2020)",Inactivated (inactivated + alum); CoronaVac (formerly PiCoVacc),"NCT04383574, NCT04352608, NCT04456595,  NCT04551547, NCT04508075, NCT04582344, NCT04617483, NCT04651790, 669/UN6.KEP/EC/2020",Unknown,"Sinovac (http://www.sinovac.com/?optionid=754&auto_id=904), medRxiv (https://www.medrxiv.org/content/10.1101/2020.07.31.20161216v1), http://www.sinovac.com/?optionid=754&auto_id=910, The Lancet (https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30843-4/fulltext), The Lancet (https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30987-7/fulltext), Sinovac (http://www.sinovac.com/?optionid=754&auto_id=922)",Same platform as vaccine candidates for SARS,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/11/2021
Wuhan Institute of Biological Products/ Sinopharm,Vaccine,Inactivated virus,Phase III,"Applied for regulatory approval in China as of February 2021; Phase III trial began July 2020; Phase I/II early trial results released June 2020, Phase I/II interim analysis published August 2020; Received early approval for ""emergency use"" in China (Aug 2020) and the UAE (Sep 2020)",Inactivated," ChiCTR2000031809, ChiCTR2000034780, ChiCTR2000039000, NCT04510207, NCT04612972",Unknown,"CNBG (https://www.cnbg.com.cn/content/details_12_5545.html), JAMA (https://jamanetwork.com/journals/jama/fullarticle/2769612)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/22/2021
Erciyes University,Vaccine,Inactivated virus,Phase II,"Phase II dosed February 2021; Phase I began November 2020, completed on December 14, 2020 ",Inactivated; (ERUCOV-VAC),NCT04691947,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/12/2021
"Shenzhen Kangtai Biological Products Co.,Ltd./ Beijing Minhai Biotechnology Co., Ltd.",Vaccine,Inactivated virus,Phase II,Phase I/II study began October 2020,Inactivated SARS-CoV-2 vaccine (Vero cell),"ChiCTR2000038804, ChiCTR2000039462 ",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/31/2021
"Valneva/ Dynavax/ National Institute for Health Research, United Kingdom",Vaccine,Inactivated virus,Phase I/II,Phase I/II began December 2020,"Inactivated (Inactivated + CpG 1018), VLA2001",NCT04671017,Unknown,,Same platform as vaccine candidates for Japanese Encephalitis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/31/2021
Shifa Pharmed Industrial Co,Vaccine,Inactivated virus,Phase I,Phase I began end of December 2020,COVID-19 inactivated vaccine (COVIran Barekat),IRCT20201202049567N1,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/4/2021
"Government
  Pharmaceutical Organization (GPO; Thailand) / Dynavax / PATH",Vaccine,Inactivated virus,Pre-clinical,Unknown,"Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro) + CpG 1018",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/9/2020
"Institute
  Butantan (Brazil) / Dynavax / PATH",Vaccine,Inactivated virus,Pre-clinical,Unknown,"Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro) + CpG 1018",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/9/2020
Institute of Vaccines and Medical Biologicals (IVAC; Vietnam) / Dynavax / PATH,Vaccine,Inactivated virus,Pre-clinical,Unknown,"Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro) + CpG 1018",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/9/2020
KM Biologics,Vaccine,Inactivated virus,Pre-clinical,Unknown,Inactivated (inactivated + alum),,Unknown,,"Same platform as vaccine candidates for JE, Zika",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Kocak Farma Ilac ve Kimya San. A.S.,Vaccine,Inactivated virus,Pre-clinical,Unknown,Inactivated,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/9/2020
"National Research Centre, Egypt",Vaccine,Inactivated virus,Pre-clinical,Unknown,Inactivated whole virus,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
Osaka University / BIKEN / NIBIOHN,Vaccine,Inactivated virus,Pre-clinical,Unknown,Inactivated,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Selcuk University,Vaccine,Inactivated virus,Pre-clinical,Unknown,Inactivated,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/23/2020
Sinovac/ Dynavax,Vaccine,Inactivated virus,Pre-clinical,Unknown,Inactivated + adjuvant (CpG 1018),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2020
Codagenix / Serum Institute of India,Vaccine,Live attenuated virus,Phase I,"Phase I trial dosed January 2021, initial data expected by mid-2021; Phase I recruitment began December 2020","Single-dose, intranasal, live attenuated vaccine, (COVI-VAC)",NCT04619628,Unknown,,"Same platform as vaccine candidates for HAV, InfA, ZIKV, FMD, SIV, RSV, DENV ",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/31/2021
Indian Immunologicals Ltd/ Griffith University,Vaccine,Live attenuated virus,Pre-clinical,Unknown,Codon deoptimized live attenuated virus,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2020
Mehmet Ali Aydinlar University/ Acıbadem Labmed Health Services A.S.,Vaccine,Live attenuated virus,Pre-clinical,Unknown,Codon deoptimized live attenuated vaccines,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Meissa Vaccines ,Vaccine,Live attenuated virus,Pre-clinical,Start Phase 1 beginning of 2021,MV-014-210,,Unknown,,Same platform as vaccine candidates for RSV,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/2/2020
Janssen Pharmaceutical Companies/ Beth Israel Deaconess Medical Center/ Emergent BioSolutions/ Catalent/ Biological E/ Grand River Aseptic Manufacturing (GRAM)/ Sanofi/ Merck,Vaccine,Non-replicating viral vector,Authorized,"Granted ""Interim Order (IO) authorization"" for emergency use by Health Canada on 3/5/2021; U.S. CDC's Advisory Committee on Immunization Practices (ACIP) has recommended the first single-shot COVID-19 vaccine for individuals 18 years of age and older on 2/28/2021; U.S. FDA issued ""emergency use authorization"" on 2/27/2021; Submitted ""emergency use listing"" to the World Health Organization (WHO) on 2/19/2021; Submitted ""conditional marketing authorisation application"" to the European Medicines Agency (EMA) on 2/16/2021; Janssen submitted application for ""emergency use authorization"" to the U.S. FDA on 2/4/2021; Phase III interim analysis results announced 1/29/2021; Phase I/IIa interim results published 1/13/2021; Phase III trial to study the safety and efficacy of a two-dose regimen began 11/15/2020 (ENSEMBLE 2); Phase III trial (ENSEMBLE) resumed recruitment on 10/23/2020, fully enrolled with ~45,000 participants as of 12/17/2020, interim data expected by the end of January 2021; Janssen Pharmaceutical Companies of Johnson & Johnson voluntarily paused dosing to allow independent review of safety data on 10/12/2020; Phase III trial (ENSEMBLE) began and study protocol released September 2020; Phase I/IIa began end of July 2020, interim results released September 2020; Animal study results published July and September 2020; Selected for US Operation Warp Speed in February 2020 and awarded funding in August 2020","Ad26.COV2-S (or JNJ-78436725), Non replicating viral vector; Ad26 (alone or with MVA boost)","EudraCT 2020-002584-63, ISRCTN14722499, NCT04436276, NCT04505722, NCT04509947, NCT04535453, NCT04614948, NCT04765384",Biomedical Advanced Research and Development Authority (BARDA),"medRxiv (https://www.medrxiv.org/content/10.1101/2020.09.23.20199604v1), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2034201), Johnson & Johnson (https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial)","Same platform as vaccine candidates for Ebola, HIV, RSV",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/9/2021
"University of Oxford, Oxford Biomedica, Vaccines Manufacturing and Innovation Centre, Pall Life Sciences, Cobra Biologics, HalixBV, Advent s.r.l., Merck KGaA, the Serum Institute, Vaccitech, Catalent, CSL, and AstraZeneca/IQVIA",Vaccine,Non-replicating viral vector,Authorized,"World Health Organization (WHO) granted Emergency Use Listing (EUL) on 2/15/2021; Phase II study in children between the ages of 6 and 17 years expected to begin in February 2021; Phase III (U.K., Brazil) and Phase I/II (U.K., South Africa) analyses data released on 2/3/2021; European Union (EU) granted ""conditional marketing authorisation"" on 1/29/2021; Brazil granted ""temporary authorization for emergency use"" on 1/17/2021; Pakistan granted ""emergency use authorization"" on 1/15/2021; India granted ""emergency use authorisation"" as well as Dominican Republic, El Salvador, Mexico and Morocco as of 1/6/2021; Argentina authorized under ""emergency registration"" on 12/30/2020;  U.K. ""authorised for emergency supply"" on 12/30/2020; Phase I/II data (w/ booster dose) published on 12/17/2020; Phase III trials interim analysis results published 12/8/2020; Phase II/III (COV002) and Phase III (COV003) trial pooled interim analysis results released on 11/23/2020; Phase II/III trial interim results released Nov 2020; Study protocol for late-stage clinical trials released September 2020; AstraZeneca clinical trials resumed globally (in the UK on 9/14/2020, Brazil and South Africa on 9/15/2020, Japan on 10/2/2020, and the US on 10/23/2020); AstraZeneca voluntarily paused vaccination to allow independent review of safety data on 9/8/2020; Phase III trial began Jun 2020 and expanded into US in Aug 2020; Phase II/III began May 2020; Phase I/II trial interim results released Jul 2020; Selected for US Operation Warp Speed in May 2020","Non replicating viral vector; COVID-19 Vaccine AstraZeneca (formerly AZD1222), (formerly ChAdOx1), (Covishield in India)"," CTRI/2020/08/027170, EudraCT 2020-001072-15, EudraCT 2020-001228-32, ISRCTN15638344, ISRCTN89951424, NCT04324606, NCT04400838, NCT04444674, NCT04516746, NCT04540393, NCT04568031, NCT04686773, PACTR202005681895696, PACTR202006922165132","Coalition for Epidemic Preparedness Innovations (CEPI)/ UK Government/ Biomedical Advanced Research and Development Authority (BARDA)/ Gavi, the Vaccine Alliance","The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31604-4/fulltext), The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32466-1/fulltext), AstraZeneca (https://sputnikvaccine.com/newsroom/pressreleases/second-interim-analysis-of-clinical-trial-data-showed-a-91-4-efficacy-for-the-sputnik-v-vaccine-on-d/), The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext), Nature Medicine (https://www.nature.com/articles/s41591-020-01179-4), Nature Medicine (https://www.nature.com/articles/s41591-020-01194-5), Preprints with The Lancet (https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3777268)","Same platform as vaccine candidates for influenza, TB, Chikungunya, Zika, MenB, plague",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/16/2021
CanSino Biologics/ Beijing Institute of Biotechnology/ Petrovax ,Vaccine,Non-replicating viral vector,Phase III,"Filed ""conditional marketing authorization"" with China's National Medical Products Administration (NMPA) on 2/24/2021; Phase III dosed September 2020; Phase II began April 2020, initial results released May 2020, mid-phase results released July 2020; China’s Central Military Commission ""approved the use of the vaccine by the military"" in June 2020","Non-replicating viral vector; Adenovirus Type 5 vector (Ad5-nCoV), (Convidecia™)","ChiCTR2000030906, ChiCTR2000031781, NCT04313127, NCT04341389, NCT04398147, NCT04526990, NCT04540419, NCT04552366, NCT04566770, NCT04568811",Unknown,"The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31208-3/fulltext), The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31605-6/fulltext)",Same platform as vaccine candidates for EBOV  ,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/25/2021
Gamaleya Research Institute,Vaccine,Non-replicating viral vector,Phase III,"Announced the start of the rolling review process with the European Medicines Agency (EMA) on 3/4/2021; Authorized for ""emergency use"" in 39 countries as of March 2021; Phase III interim analysis results published on 2/2/2021; ""Registered"" in Belarus in December 2020; Phase III final control point data analysis results released December 2020, interim data analysis results released November 2020; Phase III (post-registration) trial began September 2020; Phase I/2 began June 2020, results published September 2020; Russian Ministry of Health ""registered"" vaccine in August 2020, Mass production expected to begin September 2020",Adeno-based; (Gam-COVID-Vac) (Sputnik V),"NCT04436471, NCT04437875, NCT04530396, NCT04564716, NCT04587219, NCT04640233, NCT04642339, NCT04656613, NCT04713488, NCT04741061",Russian Direct Investment Fund (RDIF),"The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31866-3/fulltext), Gamaleya Center and RDIF (https://sputnikvaccine.com/newsroom/pressreleases/the-first-interim-data-analysis-of-the-sputnik-v-vaccine-against-covid-19-phase-iii-clinical-trials-/), Gamaleya Center and RDIF (https://sputnikvaccine.com/newsroom/pressreleases/second-interim-analysis-of-clinical-trial-data-showed-a-91-4-efficacy-for-the-sputnik-v-vaccine-on-d/), The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00234-8/fulltext)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/9/2021
Shenzhen Geno-Immune Medical Institute,Vaccine,Non-replicating viral vector,Phase I/II,Phase I/II reportedly began March 2020,LV-SMENP-DC vaccine and antigen-specific CTLs,NCT04276896,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/31/2021
"City of
  Hope Medical Center",Vaccine,Non-replicating viral vector,Phase I,Phase I dosed December 2020,MVA-based SARS-CoV-2 vaccine; (COH04S1),NCT04639466,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/27/2021
German Center for Infection Research (DZIF)/ IDT Biologika GmbH/ Universitätsklinikum Hamburg-Eppendorf/ Philipps University Marburg Medical Center/ Ludwig-Maximilians University of Munich,Vaccine,Non-replicating viral vector,Phase I,"Clinical testing suspended January 2021, Phase II postponed until further notice; Phase I dosed October 2020",Non-replicating viral vector; MVA-S encoded,NCT04569383,Unknown,,Same platform as vaccine candidates for many pathogens,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/14/2021
ImmunityBio/ NantKwest,Vaccine,Non-replicating viral vector,Phase I,"FDA authorized the expansion of the active Phase I trial and a second trial to test a novel combination of T-cell-based hAd5 subcutaneous prime vaccine with a room-temperature oral or sublingual boost; Phase I trial expected to begin in South Africa in February 2021; Phase I interim data announced November 2020; Pre-clinical data released December, November, and July 2020; Phase I trial dosed in the U.S. in October 2020; Selected for US Operation Warp Speed in May 2020","Non-replicating viral vector; [E1-, E2b-, E3-] hAd5-COVID19-Spike/Nucleocapsid","NCT04591717, NCT04710303, NCT04732468",Unknown,,"Same platform as vaccine candidates for flu, Chik, Zika, EBOV, LASV, HIV/SIV, cancer",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/12/2021
ReiThera/ Leukocare/ Univercells/ National Institute of Infectious diseases Lazzaro Spallanzani,Vaccine,Non-replicating viral vector,Phase I,"Phase II/III is expected to begin in the coming months; Phase I advanced to second set of three cohorts (aged 65-85 years) in November 2020; Phase I began August 2020, completed the first set of three cohorts (aged 18-55 years), preliminary results announced November 2020; Phase II/III trial expected to begin in the coming months",Non-replicating viral vector; replication defective simian adenovirus encoding SARS-CoV-2 S (GRAd-CoV2),"EudraCT 2020-002835-31, EudraCT 2020-005915-39, NCT04528641",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/9/2021
Vaxart/ Emergent BioSolutions,Vaccine,Non-replicating viral vector,Phase I,"Phase II expected to begin Q2 2021; Phase I preliminary data announced 2/3/2021; Phase I dosed October 2020; FDA clearance for Phase I trial received September 2020, recruiment expected to begin September 2020; Pre-clinical results released September 2020; Data from ongoing animal challenge study released October and November 2020","Non-replicating viral vector; Oral Vaccine
 platform",NCT04563702,Unknown,Vaxart (https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-positive-preliminary-data-phase-1-clinical),"Same platform as vaccine candidates for InfA, CHIKV, LASV, NORV, EBOV, RVF, HBV, VEE",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/9/2021
Altimmune / University of Alabama at Birmingham,Vaccine,Non-replicating viral vector,Pre-clinical,Phase I commenced enrollment on 2/25/2021; Phase I expected to begin February 2021; FDA issued clinical hold for planned Phase I trial on 12/22/2020;Pre-clinical data released October 2020,"AdCOVID; single-dose, intranasal vaccine; non replicating viral vector; adenovirus-based NasoVAX expressing spike protein",NCT04679909,Unknown,,Same platform as vaccine candidates for influenza,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/27/2021
Ankara University,Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Adenovirus-based,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Bharat Biotech International Limited,Vaccine,Non-replicating viral vector,Pre-clinical,Phase I expected to begin March 2021,"BBV154; adenovirus vectored, intranasal vaccine",NCT04751682,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/27/2021
Bharat Biotech/ Thomas Jefferson University,Vaccine,Non-replicating viral vector,Pre-clinical,Pre-clinical data published October 2020,Recombinant deactivated rabies virus containing S1; (CoraVax),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/27/2021
"CanSino Biologics/ Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China",Vaccine,Non-replicating viral vector,Pre-clinical,Phase I recruitment began end of September 2020,Ad5-nCoV,NCT04552366,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/2/2020
"Centro Nacional Biotecnologia (CNB-CSIC), Spain",Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,"Non-replicating viral vector, MVA expressing structural proteins",,Unknown,,"Same platform as vaccine candidates for HIV, HCV, CHIKV, EBOV, Zika, Malaria, Leishmania",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Erciyes University,Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Adeno5-based,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/3/2020
GeoVax / BravoVax/ NIAID/ NIH/ University of Texas Medical Branch ,Vaccine,Non-replicating viral vector,Pre-clinical,"Awarded a Small Business Innovative Research (SBIR) grant in January 2021 to support the ongoing design, construction, and preclinical testing in preparation for human clinical trials",Non-replicating viral vector; MVA encoded VLP,,National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH),,"Same platform as vaccine candidates for LASV, EBOV, MARV, HIV",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/25/2021
"Globe Biotech Limited, Bangladesh",Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Adenovirus Type 5 Vector,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/9/2020
Greffex,Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Non-replicating viral vector; Ad5 S (GREVAX™ platform),,Unknown,,"Same platform as vaccine candidates for MERS
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
ID Pharma,Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Sendai virus vector,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
"IDIBAPS- Hospital Clinic, Spain",Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,MVA-S,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/1/2020
"Institut
  Pasteur/ TheraVectys",Vaccine,Non-replicating viral vector,Pre-clinical,Animal study results released July 2020,Intranasal lentiviral vector vaccine,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/2/2020
"Massachusetts Eye and Ear/ AveXis, a Novartis Company/  Viralgen/ Aldevron/ Catalent/ Penn Medicine",Vaccine,Non-replicating viral vector,Pre-clinical,Pre-clinical results released January 2021; Phase I to begin second half of 2020,"AAVCOVID, Adeno-associated viral vector (AAV), spike protein",,Gates Foundation,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/29/2021
"National
  Research Centre, Egypt",Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Influenza A H1N1 vector,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
"National Center for Genetic Engineering and Biotechnology (BIOTEC)/ GPO, Thailand",Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Inactivated Flu-based SARS-CoV2 vaccine + Adjuvant,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/1/2020
Stabilitech Biopharma Ltd,Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Oral Ad5 S,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
University of Georgia/ University of Iowa,Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Non-replicating viral vector; parainfluenza virus 5 (PIV5)-based vaccine expressing the spike protein,,Unknown,,Same platform as vaccine candidates for MERS ,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2020
University of Helsinki/ University of Eastern Finland,Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Ad 5 vector for intranasal administration,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/9/2020
Valo Therapeutics Ltd,Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Adenovirus-based + HLA-matched peptides (Pan-Corona),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
"Anhui Zhifei Longcom Biopharmaceutical/ Institute of Microbiology, Chinese Academy of Sciences",Vaccine,Protein subunit,Phase III,Phase III began December 2020; Phase I and II safety and immunogenicity data released December 2020; Phase II began July 2020; Received approval to launch clinical trials in China in June 2020,Adjuvanted recombinant protein (RBD-Dimer); ( ZF2001),"NCT04445194, NCT04466085, NCT04550351, NCT04646590",Unknown,medRxiv (https://www.medrxiv.org/content/10.1101/2020.12.20.20248602v1),Same platform as vaccine candidates for MERS,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,12/30/2020
Instituto Finlay de Vacunas,Vaccine,Protein subunit,Phase III,Phase III began March 2021; Phase II began December 2020; Phase I began October 2020,rRBD produced in CHO-cell chemically conjugate to tetanus toxoid; (FINLAY-FR-2) (SOBERANA 02),"IFV/COR/06 (RPCEC00000340), IFV/COR/08 (RPCEC00000347), IFV/COR/09 (RPCEC00000354)",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/9/2021
Novavax/Emergent Biosolutions/ Praha Vaccines/ Biofabri/ Fujifilm Diosynth Biotechnologies/ FDB/ Serum Institute of India/ SK bioscience/ Takeda Pharmaceutical Company Limited/ AGC Biologics/ PolyPeptide Group/ Endo,Vaccine,Protein subunit,Phase III,"Announced the start of the rolling review process with several regulatory agencies worldwide on 2/4/2021, including the European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA), U.K. Medicines and Healthcare products Regulatory Agency (MHRA), and Health Canada; Phase III (UK) and Phase IIb ( South Africa) results released 1/28/2021; Phase III trial (PREVENT-19) initiated in the US and Mexico in December 2020, trial protocol released on website; FDA granted Fast Track Designation on 11/9/2020; Phase III dosed in the UK in October 2020, trial protocol released on website, interim data expected to be released in Q1 2021; Phase IIb trial began Aug 2020; Selected for US Operation Warp Speed July 2020; Phase I/II began end of May 2020, interim data expected to be released on 10/30/2020; Animal study & preliminary Phase I results released Aug 2020, Phase I results published Sept 2020",Protein subunit; Full length recombinant SARs COV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M; (NVX-CoV2373) (SARS-CoV-2 rS),"EudraCT 2020-004123-16, NCT04368988, NCT04533399, NCT04583995, NCT04611802",Coalition for Epidemic Preparedness (CEPI)/ US Department of Defense/ Gates Foundation,"medRxiv (https://www.medrxiv.org/content/10.1101/2020.08.05.20168435v1), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2026920), Novavax (https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3)","Same platform as vaccine candidates for RSV, CCHF, HPV, VZV, EBOV",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/2/2021
Medigen Vaccine Biologics Corp/ NIAID/ Dynavax,Vaccine,Protein subunit,Phase II,Phase II dosed January 2021; Phase I dosed in early October 2020; Received conditional approval for clinical testing on Aug 31 and was given full approval on Sept 30; Pre-clinical data released August 2020 and published November 2020,MVC-COV1901 vaccine injection; S-2 P protein + CpG 1018,"NCT04487210, NCT04695652",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/28/2021
Sanofi Pasteur/ GSK,Vaccine,Protein subunit,Phase II,Phase II with refined antigen formulation began February 2021; Phase I/II interim safety and immunogenicity results released January 2021; Phase IIb expected to begin February 2021; Phase I/II interim results announced December 2020; Phase I/II began September 2020; Selected for US Operation Warp Speed in April 2020 and awarded funding in July 2020 ,"Protein subunit; S protein, baculovirus production","NCT04537208, NCT04762680, PACTR202011523101903",Biomedical Advanced Research and Development Authority (BARDA)/ US Department of Health and Human Services (HHS)/ US Department of Defense (DoD),"Sanofi and GSK (https://www.sanofi.com/en/media-room/press-releases/2020/2020-12-11-07-00-00), medRxiv (https://www.medrxiv.org/content/10.1101/2021.01.19.20248611v1.full)","Same platform as vaccine candidates for Influenza, SARS-CoV (FDA approved vaccine)",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/9/2021
"West China Hospital, Sichuan University",Vaccine,Protein subunit,Phase II,Phase II began November 2020; Phase I began end of August 2020; Animal study data published July 2020,"RBD (baculovirus production
expressed in Sf9 cells)","ChiCTR2000037518, ChiCTR2000039994, NCT04530656, NCT04640402, NCT04718467",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/4/2021
Biological E Ltd/ Dynavax/ Baylor College of Medicine,Vaccine,Protein subunit,Phase I/II,"CEPI partnership announced December 2020; Phase I/II began November 2020, interim data expected Q1 2021",Protein subunit; (BECOV2),CTRI/2020/11/029032,Coalition for Epidemic Preparedness Innovations (CEPI),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/5/2021
"Center for Genetic Engineering and Biotechnology (CIGB), Havana",Vaccine,Protein subunit,Phase I/II,Phase I of Phase I/II (MAMBISA) trial began December 2020,CIGB-669 (RBD-AgnHB),RPCEC00000345,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/31/2021
"Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology ""VECTOR""",Vaccine,Protein subunit,Phase I/II,Efficacy results expected to be announced in February 2021; Received early approval for use in Russia in October 2020; Phase I/II trial began end of July 2020,"Peptide vaccine, EpiVacCorona",NCT04527575,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/19/2021
Instituto Finlay de Vacunas,Vaccine,Protein subunit,Phase I/II,Phase I/II began August 2020 ,RBD + Adjuvant (FINLAY-FR-1) (SOBERANA 01),"IFV/COR/04 (RPCEC00000332), IFV/COR/05 (RPCEC00000338)",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/9/2021
"Nanogen
  Pharmaceutical Biotechnology",Vaccine,Protein subunit,Phase I/II,Phase I/II began December 2020,"Recombinant SARS-CoV-2 spike protein, aluminum adjuvanted",NCT04683484,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/5/2021
"Shionogi & Co., Ltd./ National Institute of Infectious Disease, Japan",Vaccine,Protein subunit,Phase I/II,Phase I/II began December 2020,"Recombinant protein vaccine S-268019, baculovirus expression",jRCT2051200092,Japan Agency for Medical Research and Development ,,Same platform as vaccine candidates for Influenza,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/5/2021
"VIDO-InterVac, University of Saskatchewan",Vaccine,Protein subunit,Phase I/II,Phase I/II dosed February 2021; Animal testing results expected in April 2020,"Protein subunit, adjuvanted microsphere peptide, (COVAC-1 & COVAC-2)",NCT04702178,The Government of Saskatchewan and the Canadian Federal Government,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/27/2021
"Adimmune
  Corporation",Vaccine,Protein subunit,Phase I,Phase I began end of August 2020; Phase II expected to begin November 2020,"Baculovirus-insect cells expression system, spike (S) protein (tAdimrSC-2f)",NCT04522089,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/2/2020
"Center for Genetic Engineering and Biotechnology (CIGB), Havana",Vaccine,Protein subunit,Phase I,"Phase II expected to begin February 2021, Phase I (ABDALA) trial began December 2020",CIGB-66 (RBD + aluminum hydroxide),RPCEC00000346,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/31/2021
Clover Biopharmaceuticals Inc./ Dynavax,Vaccine,Protein subunit,Phase I,"Clover and GSK discontinued their partnership as of February 2021; Phase I safety and immunogenicity data released December 2020 and published January 2021; Phase II/III trial with Dynavax adjuvant expected to begin during first half of 2021; Phase II/III trial with GSK adjuvant is not expected to move forward; Pre-clinical results released September 2020; CEPI partnership expanded in July and November 2020, Phase I trial began June 2020, preliminary results expected in the near future","Protein subunit, native like trimeric subunit spike protein; (SCB-2019)","NCT04405908, NCT04672395",Coalition for Epidemic Preparedness (CEPI),"Clover Biopharmaceuticals (http://www.cloverbiopharma.com/index.php?m=content&c=index&a=show&catid=11&id=53), medRxiv (https://www.medrxiv.org/content/10.1101/2020.12.03.20243709v1), The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00241-5/fulltext)","Same platform as vaccine candidates for HIV, RSV, Influenza",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/11/2021
Covaxx/ University of Nebraska Medical Center (UNMC)/ DASA/ United Biomedical Inc. Asia,Vaccine,Protein subunit,Phase I,"Phase I interim data announced 2/8/2021; Phase II began February 2021; Phase II clinical trials granted conditional approval by Taiwan's Ministry of Health and Welfare on 1/29/2021; Phase II/III expected to begin (US, Brazil, Taiwan, and India) in early 2021; Phase I began September 2020; Large scale human efficacy clinical trials expected to be conducted in Brazil and the US",S1-RBD-protein; Multitope Peptide-Based Vaccine (MVP); UB-612,"NCT04545749, NCT04683224, NCT04773067",Ministry of Health and Welfare in Taiwan,COVAXX (https://www.businesswire.com/news/home/20210208005198/en),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/9/2021
Razi Vaccine and Serum Research Institute,Vaccine,Protein subunit,Phase I,Phase I began end of February 2021,SARS-CoV-2 recombinant Spike protein vaccine (Razi Cov Pars),IRCT20201214049709N1,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/4/2021
University Hospital Tuebingen,Vaccine,Protein subunit,Phase I,Phase I began December 2020,"SARS-CoV-2 HLA-DR peptides, (CoVAC-1)",NCT04546841,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/27/2021
Vaxine Pty Ltd/ Flinders University/ Oracle/ Medytox/ Sypharma/ Oxford Expression Technologies,Vaccine,Protein subunit,Phase I,Phase I trial began July 2020,Protein subunit; recombinant spike protein with Advax adjuvant (COVAX-19),NCT04453852,Innovate UK/ Australian Government,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,10/1/2020
AdaptVac (PREVENT-nCoV consortium),Vaccine,Protein subunit,Pre-clinical,Pre-clinical data published January 2021; initial Phase I/IIa results expected to be released in Q1 2021,"Protein subunit, capsid-like particle (CLP)",,European Commission (Horizon 2020 Program),,Same platform as vaccine candidates for HPV  ,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/25/2021
AJ Vaccines,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; S protein,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
AnyGo Technology,Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, recombinant S1-Fc fusion protein",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
"Applied Biotechnology Institute, Inc.",Vaccine,Protein subunit,Pre-clinical,Unknown,"Orally delivered, heat stable subunit",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/12/2020
Axon Neuroscience SE,Vaccine,Protein subunit,Pre-clinical,Pre-clinical results released September 2020,Peptides derived from Spike protein; (ACvac1),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/16/2020
Baiya Phytopharm/ Chula Vaccine Research Center,Vaccine,Protein subunit,Pre-clinical,Unknown,Plant-based subunit (RBD-Fc + Adjuvant),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/18/2020
Baylor College of Medicine,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; S1 or RBD protein,,Unknown,,Same platform as vaccine candidates for SARS,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
BiOMVis Srl/ University of Trento,Vaccine,Protein subunit,Pre-clinical,Unknown,OMV-based vaccine,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/12/2020
Bogazici University,Vaccine,Protein subunit,Pre-clinical,Unknown,Peptide + novel adjuvant,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
"Chulalongkorn University/ GPO, Thailand",Vaccine,Protein subunit,Pre-clinical,Unknown,RBD protein fused with Fc of IgG + Adjuvant,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/1/2020
EpiVax ,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit EPV-CoV-19,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/27/2020
EpiVax / University of Georgia,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; S protein,,Unknown,,Same platform as vaccine candidates for Inf H7N9,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
ExpreS2ion,Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, drosophila S2 insect cell expression system VLPs",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Farmacológicos Veterinarios SAC (FARVET SAC) / Universidad Peruana Cayetano Heredia (UPCH),Vaccine,Protein subunit,Pre-clinical,Unknown,RBD protein (baculovirus production) + FAR-Squalene adjuvant,,Unknown,,Same platform as multiple vaccine candidates,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/19/2021
"Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology ""VECTOR""",Vaccine,Protein subunit,Pre-clinical,Unknown,Subunit vaccine ,,Unknown,,Same platform as vaccine candidates for Ebola,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/31/2020
Flow Pharma,Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, peptide",,Unknown,,"Same platform as vaccine candidates for Ebola, Marburg, HIV, Zika, Influenza, HPV therapeutic vaccine, Breast Cancer ",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Generex / EpiVax,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; Ii-Key peptide,,Unknown,,"Same platform as vaccine candidates for HIV, SARS-CoV, Influenza",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Heat Biologics (Zolovax)/ University of Miami/ Waisman Biomanufacturing,Vaccine,Protein subunit,Pre-clinical,Animal data released August 2020,Protein subunit (gp-96 backbone),,Unknown,,"Same platform as vaccine candidates for cancer (NSCLC), HIV, malaria, Zika",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/13/2020
"Helix Biogen Consult, Ogbomoso & Trinity Immonoefficient Laboratory, Ogbomoso, Oyo State, Nigeria",Vaccine,Protein subunit,Pre-clinical,Unknown,Subunit,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
iBio / CC-Pharming,Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit; Subunit protein, plant produced",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
ImmunoPrecise/ LiteVax BV,Vaccine,Protein subunit,Pre-clinical,Unknown,Spike-based (epitope screening),,TRANSVAC2,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/15/2020
"IMV, Inc., Canadian Center for Vaccinology at Dalhousie University, Izaak Walton Killam Health Center, Nova Scotia Health Authority, Canadian Immunization Research Network, University of Laval, Global Urgent and Advanced Research and Development in Canada",Vaccine,Protein subunit,Pre-clinical,Phase I/II expected to begin by end of 2020,"Protein subunit; DPX-COVID-19, protein subunit, peptide antigens formulated in LNP",,"National Research Council of Canada Industrial Research Assistance Program (NRC IRAP), Atlantic Canada Opportunities Agency (ACOA), and Next Generation Manufacturing Canada (NGen)",,"Same platform as vaccine candidates for cancer and infectious diseases, including malaria and anthrax",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/16/2020
InnoMedica,Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, TaliCoVax19 ",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Innovax / Xiamen University / GSK,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; COVID-19 XWG-03 truncated Spike proteins,,Unknown,,"Same platform as vaccine candidates for HPV  
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Intravacc/Epivax,Vaccine,Protein subunit,Pre-clinical,Unknown,Outer Membrane Vesicle (OMV)-peptide,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/19/2020
Intravacc/Epivax,Vaccine,Protein subunit,Pre-clinical,Unknown,Outer Membrane Vesicle (OMV)-subunit,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/12/2020
Izmir Biomedicine and Genome Center,Vaccine,Protein subunit,Pre-clinical,Unknown,Recombinant S protein,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Kazakh National Agrarian University,Vaccine,Protein subunit,Pre-clinical,Unknown,Recombinant spike protein with Essai O/W 1849101 adjuvant,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/10/2020
"Kazakh National Agrarian University, Kazakhstan/ National Scientific Center for Especially Dangerous Infections",Vaccine,Protein subunit,Pre-clinical,Unknown,Recombinant spike protein with Essai O/W 1849101 adjuvant,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/10/2020
Kentucky BioProcessing (British American Tobacco),Vaccine,Protein subunit,Pre-clinical,"Phase I/II began recruiting December 2020, results expected mid-2021","RBD-based, (KBP-COVID-19)",NCT04473690,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/27/2021
"LakePharma, Inc.",Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, nanoparticle vaccine",,Unknown,,,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
Lomonosov Moscow State University,Vaccine,Protein subunit,Pre-clinical,Unknown,Structurally modified spherical particles of the tobacco mosaic virus (TMV),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/27/2020
Max-Planck Institute of Colloids and Interfaces,Vaccine,Protein subunit,Pre-clinical,Unknown,Recombinant S protein,,KHAN-1 Technology Transfer Fund I GmbH & Co KG,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/10/2020
MIGAL Galilee Research Institute,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; oral E. coli-based protein expression system of S and N proteins,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"MOGAM Institute for Biomedical Research, GC Pharma",Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/16/2020
Mynvax,Vaccine,Protein subunit,Pre-clinical,Unknown,RBD-protein,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/15/2020
"National
  Research Centre, Egypt",Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein Subunit S, N, M & S1 protein",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
Neo7Logix,Vaccine,Protein subunit,Pre-clinical,Unknown,Peptides,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/16/2020
Neovii/Tel Aviv University,Vaccine,Protein subunit,Pre-clinical,Unknown,RBD-based,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/19/2020
Ohio State University/ Kazakh National Agrarian University,Vaccine,Protein subunit,Pre-clinical,Unknown,RBD protein delivered in mannose-conjugated chitosan nanoparticle,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/10/2020
OncoGen,Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, synthetic long peptide vaccine candidate for S and M proteins",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"Osaka University / BIKEN / National Institutes of Biomedical Innovation, Japan",Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, VLP-recombinant protein + adjuvant",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
PDS Biotechnology,Vaccine,Protein subunit,Pre-clinical,Unknown,PDS-0203; Versamune T-cell activating technology ,,Unknown,,"Same platform as vaccines against cancers, HBV, influenza, and tuberculosis",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/2/2020
Quadram Institute Biosciences,Vaccine,Protein subunit,Pre-clinical,Unknown,OMV-based vaccine,,Unknown,,"Same platform as vaccine candidates for Flu A, plaque
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/12/2020
"Research
  Institute for Biological Safety Problems, Rep of Kazakhstan",Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/3/2020
SK Biosciences/ GSK,Vaccine,Protein subunit,Pre-clinical,Phase I/II enrollment began February 2021,"SARS-CoV-2 recombinant protein nanoparticle vaccine, (GBP510)","NCT04742738, NCT04750343",Gates Foundation/ Coalition for Epidemic Preparedness (CEPI),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/12/2021
Soligenix/ University of Hawaii at Mānoa,Vaccine,Protein subunit,Pre-clinical,Pre-clinical testing results released in July 2020,CiVax™ COVID-19 vaccine candidate; spike protein + novel adjuvant,,"Soligenix, Inc. ",,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/27/2020
Sorrento Therapeutics,Vaccine,Protein subunit,Pre-clinical,Animal study results released July 2020,Recombinant fusion protein of the SARS-CoV-2 spike protein S1 domain and human IgG Fc (T-VIVA-19),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/17/2020
St. Petersburg Scientific Research Institute of Vaccines and Serums,Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, recombinant protein, nanoparticles (based on S-protein and other epitopes)",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Tampere University,Vaccine,Protein subunit,Pre-clinical,Unknown,Recombinant S protein produced in BEVS,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/10/2020
UMN Pharma (Shionogi),Vaccine,Protein subunit,Pre-clinical,Phase I to start by end of 2020,"Protein subunit; recombinant protein vaccine, utilizing baculovirus expression vector system technology",,Japan Agency for Medical Research and Development,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/10/2020
University  Medical Center Groningen/ Akston Biosciences Corporation/ LakePharma,Vaccine,Protein subunit,Pre-clinical,Phase I/II expected to begin January 2021,SARS-CoV-2-RBD-Fc fusion protein; (AKS-452),NCT04681092,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/12/2021
University of Alberta,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; spike based,,Unknown,,Same platform as vaccine candidates for Hepatitis C,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"University of California, San Diego",Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; plant virus nanotechnology formulated as injectable and microneedle patch,,National Science Foundation (Rapid Response Research [RAPID] grant),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2020
University of Pittsburgh,Vaccine,Protein subunit,Pre-clinical,Phase I to start as early as June 2020,"PittCoVacc, Protein subunit, microneedle arrays S1 subunit",,Unknown,,Same platform as vaccine candidates for MERS,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"University of San Martin and CONICET, Argentina",Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/12/2020
University of Virginia,Vaccine,Protein subunit,Pre-clinical,Unknown,S subunit intranasal liposomal formulation with GLA/3M052 adjs.,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
Vabiotech,Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, recombinant S protein in IC-BEVS  ",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/16/2020
Vaxil Bio,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; peptide,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"Verndari/ University of California, Davis",Vaccine,Protein subunit,Pre-clinical,"Preliminary pre-clinical results are expected in the second half of 2020, Phase I trial is expected to begin thereafter; Selected by BARDA DRIVe for support in August 2020",Spike protein; VaxiPatch microneedle array dermal patch,,"Biomedical Advanced Research and Development Authority (BARDA) Division of Research, Innovation, and Ventures (DRIVe)",,Same platform as vaccines against influenza,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/27/2020
Walter Reed Army Institute of Research (WRAIR) / U.S. Army Medical Research and Development Command,Vaccine,Protein subunit,Pre-clinical,Phase I expected to begin April 2021,Protein subunit; S protein (SpFN),NCT04784767,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/9/2021
Yisheng Biopharma,Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, recombinant protein  ",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
The University of Hong Kong/ Xiamen University/ Wantai Biological Pharmacy,Vaccine,Replicating viral vector,Phase II,Phase II reportedly began November 2020; Phase I reportedly began September 2020; ; Approved for clinical trials in September 2020,"Replicating viral vector, intranasal flu-based RBD (DelNS1-2019-nCoV-RBD-OPT1)","ChiCTR2000037782, ChiCTR2000039715",Coalition for Epidemic Preparedness (CEPI),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/31/2021
"Cellid
  Co., Ltd./IAVI",Vaccine,Replicating viral vector,Phase I/II,Phase I/IIa trial began December 2020,AdCLD-CoV19,NCT04666012,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/31/2021
"Israel
  Institute for Biological Research/ Weizmann Institute of Science",Vaccine,Replicating viral vector,Phase I/II,Phase I/II began November 2020,rVSV-SARS-CoV-2-S vaccine,NCT04608305,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/31/2021
"Aivita Biomedical, Inc./ National Institute of Health Research and Development, Ministry of Health Republic of Indonesia",Vaccine,Replicating viral vector,Phase I,Phase I/II expected to begin February 2021; Phase I began December 2020,Dendritic cell vaccine AV-COVID-19,"NCT04690387, NCT04685603, NCT04386252",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/31/2021
Shenzhen Geno-Immune Medical Institute,Vaccine,Replicating viral vector,Phase I,Phase I reportedly began February 2020,Covid-19/aAPC vaccine,NCT04299724,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/31/2021
Aurobindo,Vaccine,Replicating viral vector,Pre-clinical,Unknown,VSV-S,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/15/2020
BIOCAD / IEM,Vaccine,Replicating viral vector,Pre-clinical,Unknown,"Replicating viral vector, live viral vectored vaccine based on attenuated influenza virus backbone (intranasal)",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
DZIF - German Center for Infection Research/ CanVirex AG,Vaccine,Replicating viral vector,Pre-clinical,Unknown,"Measles virus (S, N targets)",,Unknown,,"Same platform as vaccine candidates for Zika, H7N9, CHIKV",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
"Farmacológicos
  Veterinarios SAC (FARVET SAC)",Vaccine,Replicating viral vector,Pre-clinical,Unknown,Intranasal Newcastle disease virus vector (rNDV-FARVET) expressing S1 protein,,Unknown,,Same platform as multiple vaccine candidates,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/19/2021
Farmacológicos Veterinarios SAC (FARVET SAC),Vaccine,Replicating viral vector,Pre-clinical,Unknown,Intranasal Newcastle disease virus vector (rNDV-FARVET) expressing RBD protein,,Unknown,,Same platform as multiple vaccine candidates,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/19/2021
"Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology ""VECTOR""",Vaccine,Replicating viral vector,Pre-clinical,Unknown,Replicating viral vector; measles vector,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/31/2020
"Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology ""VECTOR""",Vaccine,Replicating viral vector,Pre-clinical,Unknown,Replicating viral vector; VSV vector,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/31/2020
"Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology ""VECTOR""",Vaccine,Replicating viral vector,Pre-clinical,Unknown,"Replicating viral vector, recombinant vaccine based on Influenza A virus, for the prevention of COVID-19 (intranasal)",,Unknown,,Same platform as vaccine candidates for influenza,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/31/2020
Fundacao Oswaldo Cruz and Instituto Buntantan,Vaccine,Replicating viral vector,Pre-clinical,Unknown,Attenuated Influenza expressing an antigenic portion of the Spike protein,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/27/2020
Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ.,Vaccine,Replicating viral vector,Pre-clinical,Unknown,Newcastle disease virus vector (NDV-SARS-CoV-2/Spike),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/19/2020
KU Leuven,Vaccine,Replicating viral vector,Pre-clinical,Unknown,Replicating viral vector; YF17D Vector,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
Mahidol University/ The Government Pharmaceutical Organization (GPO)/ Icahn School of Medicine at Mount Sinai,Vaccine,Replicating viral vector,Pre-clinical,Phase I/II expected to begin March 2021,"NDV-HXP-S vaccine, with or without the adjuvant CpG 1018 ",NCT04764422,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/27/2021
"The Lancaster University, UK",Vaccine,Replicating viral vector,Pre-clinical,Unknown,Avian paramyxovirus vector (APMV),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/19/2020
Tonix Pharma / Southern Research,Vaccine,Replicating viral vector,Pre-clinical,Unknown,Replicating viral vector; horsepox vector expressing S protein; TNX-1800,,Unknown,,"Same platform as vaccine candidates for smallpox, monkeypox",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/19/2020
University of Manitoba,Vaccine,Replicating viral vector,Pre-clinical,Unknown,Replicating VSV vector-based DC-targeting,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/9/2020
University of Western Ontario,Vaccine,Replicating viral vector,Pre-clinical,Unknown,Replicating viral vector; VSV-S,,Unknown,,"Same platform as vaccine candidates for HIV, MERS",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
University of Wisconsin-Madison / FluGen/ Bharat Biotech,Vaccine,Replicating viral vector,Pre-clinical,Start Phase I trial in fall 2020,M2-deficient single replication (M2SR) influenza vector,,Unknown,,Same platform as vaccine candidates for influenza,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
Zydus Cadila Healthcare Limited ,Vaccine,Replicating viral vector,Pre-clinical,Unknown,Replicating viral vector; measles vector,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
BioNTech/ Pfizer/ Fosun Pharma/ Rentschler Biopharma,Vaccine,RNA-based vaccine,Authorized,"Evaluation of the safety and immunogenicity of a third dose (30 µg booster of the current vaccine) 6 to 12 months after receiving initial two-dose regimen began 2/25/2021; New stability data at standard freezer temperature was submitted to the U.S. FDA as of 2/19/2021; Results from in vitro studies on neutralization of variants of SARS-CoV-2 by BNT162b2 vaccine-elicited sera announced January 2021; Phase I (China) preliminary safety and immunogenicity data released January 2021; Argentina authorized under ""emergency registration"" on 12/22/2020; European Commission granted a ""conditional marketing authorisation"" (CMA) on 12/21/2020, following European Medicines Agency (EMA) recommendation to grant CMA; U.S. FDA issued ""emergency use authorization"" on 12/11/2020; Mexico COFEPRIS granted ""emergency use authorization"" on 12/11/2020; Saudi Food and Drug Authority (SFDA) ""approved the registration"" of the vaccine on 12/10/2020; Health Canada ""authorized"" on 12/9/2020; Bahrain granted ""emergency use authorization"" on 12/4/2020; U.K. MHRA granted ""temporary authorization for emergency use"" on 12/2/2020; Submitted Emergency Use Authorization (EUA) request to the U.S. FDA on 11/20/2020; Phase III complete analysis results announced 11/18/2020, interim analysis results announced 11/09/2020; Phase I data published October 2020; FDA approved late-stage trial enrollment of children 12 years and older in October 2020; EMA rolling submission initiated on 10/6/2020; Study protocol for late-stage clinical trials released Sept 2020; Amended protocol to FDA to expand trial enrollment to 44,000 participants; Phase IIb/III trial began Jul 2020; FDA granted Fast Track designation for BNT162b1 and BNT162b2 in Jul 2020; Selected for US Operation Warp Speed in Jul 2020; Phase I/II began Apr 2020; preliminary data released Jul 2020, additional data published Aug, Sept, and Dec 2020; Pre-clinical data released Sept 2020 and Dec 2020","3 LNP-mRNAs; BNT162 
","ChiCTR2000034825, EudraCT 2020-001038-36, EudraCT 2020-003267-26, NCT04368728, NCT04380701, NCT04523571, NCT04537949, NCT04588480, NCT04649021, NCT04713553, NCT04754594",Unknown,"Pfizer (https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-early-positive-data-ongoing-0), medRxiv (https://www.medrxiv.org/content/10.1101/2020.06.30.20142570v1), medRxiv (https://www.medrxiv.org/content/10.1101/2020.07.17.20140533v1), Nature (https://www.nature.com/articles/s41586-020-2639-4), medRxiv (https://www.medrxiv.org/content/10.1101/2020.08.17.20176651v1), Nature (https://www.nature.com/articles/s41586-020-2814-7), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2027906?query=featured_home), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2034577?query=featured_home), medRxiv (https://www.biorxiv.org/content/10.1101/2020.12.11.421008v1), medRxiv (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1), Pfizer (https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-data-german-phase-12-study), bioRxiv (https://www.biorxiv.org/content/10.1101/2021.01.07.425740v1), bioRxiv (https://www.biorxiv.org/content/10.1101/2021.01.18.426984v1), Research Square (https://www.researchsquare.com/article/rs-137265/v1) ",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/9/2021
Moderna/ National Institute of Allergy and Infectious Diseases (NIAID)/ Biomedical Advanced Research and Development Authority (BARDA)/ Lonza/ Catalent/ Rovi/ Medidata/ BIOQUAL/ Baxter BioPharma Solutions,Vaccine,RNA-based vaccine,Authorized,"Provided strategy update for addressing SARS-CoV-2 variants of concern, including a variant-specific booster candidate (mRNA-1273.351) based on the B.1.351 variant first identified in the Republic of South Africa, on 2/24/2021; Results from an in vitro study on neutralization of variants of SARS-CoV-2 by mRNA-1273 vaccine-elicited sera announced January 2021; Phase I/II dosed in Japan (TAK-919) on 01/21/2021; Switzerland ""authorized"" on 01/12/2021; U.K. MHRA granted ""temporary authorization"" on 01/08/2021; European Commission granted a ""conditional marketing authorization"" on 01/06/2021; Israel granted ""authorization to import"" on 01/04/2021; Phase III interim safety and primary efficacy results published on 12/30/2020; Health Canada ""authorized"" on 12/23/2020; U.S. FDA issued ""emergency use authorization"" on 12/18/2020; Phase II/III study in adolescents ages 12 to less than 18 dosed on 12/10/2020; Submitted Emergency Use Authorization (EUA) request to the U.S. FDA on 11/30/2020; Phase III primary efficacy analysis results announced 11/30/2020; European Medicines Agency (EMA) started rolling review on 11/17/2020; Phase III interim analysis results announced 11/16/2020; Swissmedic started rolling review on 11/13/2020; UK Medicines and Healthcare products Regulatory Agency (MHRA) started rolling review on 10/27/2020; EMA confirmed marketing authorization submission eligibility on 10/14/2020; Health Canada rolling submission initiated on 10/13/2020; Study protocol for late-stage clinical trials released September 2020; Phase I interim data from older adult cohorts released Aug 2020 and published Sep 2020; Phase III COVE study began July 2020, completed enrollment on 10/22/2020; Animal study results published July/Aug 2020; Phase I interim results published July 2020; FDA fast track designation granted May 2020; Selected for US Operation Warp Speed in April 2020","RNA; LNP-encapsulated mRNA (mRNA 1273), (TAK-919)","NCT04283461, NCT04405076, NCT04470427, NCT04649151, NCT04677660, NCT04712110",Coalition for Epidemic Preparedness (CEPI)/ Biomedical Advanced Research and Development Authority (BARDA),"Moderna (https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-interim-phase-1-data-its-mrna-vaccine), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2022483), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2028436), Moderna (https://www.businesswire.com/news/home/20201116005608/en/Moderna%E2%80%99s-COVID-19-Vaccine-Candidate-Meets-Primary-Efficacy), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMc2032195), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2035389), bioRxiv (https://www.biorxiv.org/content/10.1101/2021.01.25.427948v1)",Same platform as vaccine candidates for multiple candidates,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/9/2021
CureVac/Bayer/Novartis,Vaccine,RNA-based vaccine,Phase III,"Initiated rolling submission with European Medicines Agency (EMA) on 2/12/2021; Phase III trial began December 2020; Phase IIb/III (HERALD) trial began recruiting December 2020; Phase IIa trial began end of September 2020; Phase I trial began June 2020, interim results reported November 2020; Pre-clinical data released October 2020",RNA; mRNA (CVnCoV),"EudraCT 2020-004066-19, NCT04449276, NCT04515147, NCT04652102, NCT04674189, PER-054-20",Coalition for Epidemic Preparedness (CEPI); European Commission; Gates Foundation; Defense Advanced Research Projects Agency (DARPA); German Government; European Investment Bank (EIB); German Federal Ministry of Education and Research (BMBF),,"Same platform as vaccine candidates for RABV, LASV, YFV, MERS, InfA, ZIKV, DengV, NIPV",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/4/2021
"Arcturus/Duke-NUS/ Catalent
",Vaccine,RNA-based vaccine,Phase I/II,"Phase IIa of Phase I/II trial began recruiting January 2021; Received approval to proceed with Phase II study in Singapore (December 2020) and the US (January 2021); Phase I/II interim data released December 2020; Pre-clinical results released September and December 2020; Phase I/II began August 2020, initial results expected Q4 2020; Received approval to launch clinical trials in Singapore end of July 2020",RNA; mRNA; (LUNAR-COV19),"NCT04480957, NCT04668339, NCT04728347",Unknown,,Same platform as vaccine candidates for multiple candidates,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/4/2021
Imperial College London/ VacEquity Global Health,Vaccine,RNA-based vaccine,Phase I/II,Pre-clinical results published July 2020; Phase I/II trial began June 2020,RNA; LNP-nCoVsaRNA,ISRCTN17072692,UK Government,,"Same platform as vaccine candidates for EBOV, LASV, MARV, Inf (H7N9), RABV",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/10/2020
People's Liberation Army (PLA) Academy of Military Sciences/ Walvax Biotech,Vaccine,RNA-based vaccine,Phase I,"Phase Ib began end of October 2020, Phase I trial began end of June 2020",mRNA (ARCoV),"ChiCTR2000034112, ChiCTR2000039212 ",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/27/2021
Providence Therapeutics Holdings Inc.,Vaccine,RNA-based vaccine,Phase I,Phase I dosed January 2021,PTX-COVID19-B vaccine,NCT04765436,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/27/2021
BIOCAD,Vaccine,RNA-based vaccine,Pre-clinical,Animal studies begin in April 2020,RNA; liposome-encapsulated mRNA,,Unknown,,Same platform as vaccine candidates for cancer   ,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
CanSino Biologics/Precision Nanosystems,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,RNA; mRNA lipid nanoparticle (mRNA-LNP),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/21/2020
"Centro Nacional Biotecnologia (CNB-CSIC), Spain",Vaccine,RNA-based vaccine,Pre-clinical,Unknown,RNA; Replicating defective SARS-CoV-2 derived RNAs,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Chimeron Bio/ George Mason University's National Center for Biodefense and Infectious  Disease,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,"Self amplifying RNA, self-assembling delivery system",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
China CDC / Tongji University / Stermina,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,RNA; mRNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Chula Vaccine Research Center/University of Pennsylvania,Vaccine,RNA-based vaccine,Pre-clinical,Phase I expected to begin May 2021,LNP-mRNA; (ChulaCov19),NCT04566276,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/27/2021
Curevac/GSK,Vaccine,RNA-based vaccine,Pre-clinical,"CureVac and GSK aim to develop a multi-valent candidate vaccine to address emerging variants for pandemic and endemic use; Development to begin immediately (February 2021) targeting vaccine availability in 2022, subject to regulatory approval",Next-generation multi-valent mRNA-based vaccines,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/5/2021
CureVac/UK Government (Vaccines Taskforce),Vaccine,RNA-based vaccine,Pre-clinical,Collaboration to develop and manufacture variant vaccines for commercial supply and distribution in the UK and its territories was entered in February 2021,Multiple mRNA vaccine candidates against SARS-CoV-2 variants ,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/5/2021
Daiichi-Sankyo/ University of Tokyo's Institute of Medical Science,Vaccine,RNA-based vaccine,Pre-clinical,Clinical studies expected to begin March 2021,RNA; mRNA (DS-5670),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/31/2020
Elixirgen Therapeutics/ Fujita Health University,Vaccine,RNA-based vaccine,Pre-clinical,"Clinical trials are expected to begin at Fujita Health University Hospital in Aichi, Japan in Q1 2021",srRNA (EXG-5003),,Japan Agency for Medical Research and Development (AMED),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/1/2020
eTheRNA Immunotherapies / EpiVax/ Nexelis/ REPROCELL / Centre for the Evaluation of Vaccination of the University of Antwerp,Vaccine,RNA-based vaccine,Pre-clinical,Start Phase I early 2021,RNA; mRNA in an intranasal delivery system (cross-strain protective COV-2 mRNA) vaccine for high-risk populations,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
"Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology ""VECTOR""",Vaccine,RNA-based vaccine,Pre-clinical,Unknown,RNA; mRNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,8/31/2020
Fudan University / Shanghai JiaoTong University / RNACure Biopharma,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,RNA; LNP-encapsulated mRNA cocktail encoding VLP,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Fudan University / Shanghai JiaoTong University / RNACure Biopharma,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,RNA; LNP-encapsulated mRNA cocktail encoding RBD,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
GeneOne Life Science / Houston Methodist,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,mRNA; (GLS-3000),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/5/2021
Gennova,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,"Self-amplifying
  RNA",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/15/2020
"Globe Biotech Limited, Bangladesh",Vaccine,RNA-based vaccine,Pre-clinical,Phase I/II protocol submitted to Bangladesh Medical Research Council (BMRC) on 1/17/2021 for approval to begin clinical trials,D614G variant LNP-encapsulated mRNA; (Bangavax),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/18/2021
"Greenlight Biosciences
",Vaccine,RNA-based vaccine,Pre-clinical,Unknown,"mRNA
",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/12/2020
"IDIBAPS- Hospital Clinic, Spain",Vaccine,RNA-based vaccine,Pre-clinical,Unknown,mRNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/1/2020
"Infectious Disease Research Institute/ Amyris, Inc.",Vaccine,RNA-based vaccine,Pre-clinical,Phase I expected to begin mid-2021,saRNA formulated in a NLC,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/16/2020
Max-Planck Institute of Colloids and Interfaces,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,LNP-encapsulated mRNA encoding S,,KHAN-1 Technology Transfer Fund I GmbH & Co KG,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/9/2020
"RNAimmune, Inc.",Vaccine,RNA-based vaccine,Pre-clinical,Unknown,RNA; several mRNA candidates,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
Sanofi Pasteur/ Translate Bio,Vaccine,RNA-based vaccine,Pre-clinical,Pre-clinical results released October 2020,"LNP-mRNA
",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/22/2021
Selcuk University,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,mRNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Ziphius Therapeutics/ Ghent University,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,"RNA; ZIP-1642, vaccine consists of a combination of mRNA molecules, encoding multiple SARS-CoV-2 antigens",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2020
Medicago Inc.,Vaccine,Virus-like particle,Phase II/III,Phase II part of Phase II/III trial dosed December 2020; Phase II/III began recruiting November 2020; Phase I interim results released November 2020; Phase I began July 2020,VLP; plant-derived VLP adjuvanted with GSK or Dynavax adjuvants; (CoVLP),"NCT04450004, NCT04636697, NCT04662697",Unknown,medRxiv (https://www.medrxiv.org/content/10.1101/2020.11.04.20226282v1.full),"Same platform as vaccine candidates for flu, rotavirus, norovirus, West Nile virus, and cancer",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/31/2021
Serum Institute of India/ Accelagen Pty/ SpyBiotech,Vaccine,Virus-like particle,Phase I/II,Phase I of follow up Phase I/II clinical trial adjuvanted with CpG 1018 dosed December 2020; Phase I/II began September 2020,RBD SARS-CoV-2 HBsAg VLP vaccine,"ACTRN12620000817943, ACTRN12620001308987",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/31/2021
Arizona State University ,Vaccine,Virus-like particle,Pre-clinical,Unknown,"Myxoma virus co-expressing S, M, N and E proteins ",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/12/2021
Arizona State University ,Vaccine,Virus-like particle,Pre-clinical,Unknown,"Plasmid driven production of virus like particles (VLPs) containing S, M, N and E proteins of SARS-CoV-2",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,2/12/2021
"ARTES Biotechnology
",Vaccine,Virus-like particle,Pre-clinical,Unknown,VLP; eVLP,,Unknown,,"Same platform as vaccine candidates for malaria
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
Bezmialem Vakif University,Vaccine,Virus-like particle,Pre-clinical,Unknown,VLP,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/21/2020
Doherty Institute,Vaccine,Virus-like particle,Pre-clinical,Unknown,VLP; unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
Icosavax,Vaccine,Virus-like particle,Pre-clinical,Phase I expected to begin mid-2021; Pre-clinical results published October 2020,VLP displaying the SARS-CoV-2 receptor-binding domain (RBD); (IVX-411),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/18/2020
Imophoron Ltd / Bristol University's Max Planck Centre,Vaccine,Virus-like particle,Pre-clinical,Unknown,VLP; ADDomerTM multiepitope display,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
IrsiCaixa AIDS Research/ IRTA-CReSA/ Barcelona Supercomputing Centre/ Grifols,Vaccine,Virus-like particle,Pre-clinical,Unknown,S protein integrated in HIV VLPs,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/23/2020
Mahidol University/ The Government Pharmaceutical Organization (GPO)/ Siriraj Hospital,Vaccine,Virus-like particle,Pre-clinical,Unknown,VLP + Adjuvant,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
Max-Planck Institute for Dynamics of Complex Technical Systems,Vaccine,Virus-like particle,Pre-clinical,Unknown,VLP,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/9/2020
"Medicago
  Inc./ GSK",Vaccine,Virus-like particle,Pre-clinical,Unknown,VLP (CoVLP)+ Adjuvant,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/14/2020
Medicago Inc./ Dynavax,Vaccine,Virus-like particle,Pre-clinical,Phase I to start mid-July 2020,VLP (CoVLP)+ Adjuvant (CpG 1018),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/10/2020
Middle East Technical University,Vaccine,Virus-like particle,Pre-clinical,Unknown,VLP,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
"Navarrabiomed, Oncoimmunology group",Vaccine,Virus-like particle,Pre-clinical,Unknown,"Virus-like particles, lentivirus, and baculovirus vehicles",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/1/2020
OSIVAX,Vaccine,Virus-like particle,Pre-clinical,Unknown,VLP (COVID-19 and SARS1),,European Innovation Council (EIC),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Saiba GmbH,Vaccine,Virus-like particle,Pre-clinical,Unknown,"VLP; virus-like particle, based on RBD displayed on virus-like particle",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Tampere University,Vaccine,Virus-like particle,Pre-clinical,Unknown,VLPs produced in BEVS,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/9/2020
University of Manitoba,Vaccine,Virus-like particle,Pre-clinical,Unknown,Virus-like particle-based dendritic cell-targeting vaccine,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/9/2020
University of Sao Paulo,Vaccine,Virus-like particle,Pre-clinical,Unknown,VLPs peptides/whole virus,,Unknown,,,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/19/2020
VBI Vaccines / National Research Council of Canada/ Therapure Biomanufacturing,Vaccine,Virus-like particle,Pre-clinical,Phase I/II trial expected to begin March 2021,"Enveloped virus-like particle (eVLP): Pan-coronavirus vaccine candidate, targeting COVID-19, SARS, and MERS, spike protein (VBI-2900)",NCT04773665,Unknown,,"Same platform as vaccine candidates for glioblastoma, cytomegalovirus, and Zika",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,3/2/2021
AbVision,Vaccine,Unknown,Pre-clinical,Unknown,AVI-205,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/13/2020
Adeleke University,Vaccine,Unknown,Pre-clinical,Unknown,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
"Catholic University/ Millennium Institute of Immunology and Immunotherapy/ Technological Consortium in Clinical Molecular Biomedicine, Chile",Vaccine,Unknown,Pre-clinical,Unknown,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/23/2020
Codiak BioSciences/ Ragon Institute,Vaccine,Unknown,Pre-clinical,Unknown,exoVACC exome platform,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/4/2020
Emergex Vaccines/ George Mason University's National Center for Biodefense and Infectious Diseases (NCBID),Vaccine,Unknown,Pre-clinical,Unknown,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/24/2020
HaloVax (Voltron Therapeutics) / The Vaccine & Immunotherapy Center at the Massachusetts General Hospital,Vaccine,Unknown,Pre-clinical,Animal study results by October 2020,"Self-assembling vaccine (fusion protein of a heat shock protein and Avidin, with biotinylated immunogenic peptides)",,Analog Devices Foundation,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/21/2020
ISR Immune System Regulation,Vaccine,Unknown,Pre-clinical,"Animal study results expected in Q2 2020, Phase I begins Q4 2020",ISR-50,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
NidoVax,Vaccine,Unknown,Pre-clinical,Unknown,unknown; IMT504 technology,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/18/2020
"Oragenics (Noachis Terra)/ Aragen Bioscience
",Vaccine,Unknown,Pre-clinical,Phase I expected to start in early 2021,"TerraCoV2
",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/28/2020
"OSE
  Immunotherapeutics",Vaccine,Unknown,Pre-clinical,"Clinical
  trials expected to begin end of 2020/early 2021; Pre-clinical results
  released in August 2020",T cell-based vaccine platform (CoVepiT),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,11/9/2020
Precision Vaccines Program at Boston Children's Hospital,Vaccine,Unknown,Pre-clinical,Unknown,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Tulane University,Vaccine,Unknown,Pre-clinical,Unknown,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"United
  Biomedical (UBI)/ c19",Vaccine,Unknown,Pre-clinical,,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,9/2/2020
Vault Pharma/ University of California Los Angeles,Vaccine,Unknown,Pre-clinical,Unknown,nanoparticles (vaults) as second-line defense of infection,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
Vir Biotechnology / GSK,Vaccine,Unknown,Pre-clinical,Unknown,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Vivaldi Biosciences/ Esco Aster Pte Ltd,Vaccine,Unknown,Pre-clinical,Unknown,Chimeric vaccine (coronavirus and influenza),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/2/2020
Farmacológicos Veterinarios SAC (FARVET SAC),Vaccine,Replicating bacterial vector,Pre-clinical,Unknown,Oral Salmonella enteritidis (3934Vac) based protein expression system of RBD,,Unknown,,Same platform as multiple vaccine candidates,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,1/19/2021
"University of California, Los Angeles (Horwitz Lab)",Vaccine,Replicating bacterial vector,Pre-clinical,Unknown,Recombinant LVS ΔcapB – vectored vaccine expressing multiple SARS-CoV-2 antigens,,Unknown,,Same platform as vaccines against select agents and emerging pathogens,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/10/2020